EHS
EHS

Tafamidis treats transthyretin amyloid cardiomyopathy

(HealthDay)—In patients with transthyretin amyloid cardiomyopathy, treatment with tafamidis reduces all-cause mortality and cardiovascular-related hospitalizations versus placebo, according to a study published in the Sept. 13 issue of the New England Journal of Medicine.

Source link

EHS
Back to top button